KR20070090248A - 4-시클로알킬-치환된 테트라히드로퀴놀린 유도체 및 그의약제로서의 용도 - Google Patents

4-시클로알킬-치환된 테트라히드로퀴놀린 유도체 및 그의약제로서의 용도 Download PDF

Info

Publication number
KR20070090248A
KR20070090248A KR1020077016219A KR20077016219A KR20070090248A KR 20070090248 A KR20070090248 A KR 20070090248A KR 1020077016219 A KR1020077016219 A KR 1020077016219A KR 20077016219 A KR20077016219 A KR 20077016219A KR 20070090248 A KR20070090248 A KR 20070090248A
Authority
KR
South Korea
Prior art keywords
formula
compound
inhibitors
protecting group
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077016219A
Other languages
English (en)
Korean (ko)
Inventor
힐마르 비쇼프
하이케 길렌-하에르트비크
폴크하르트 리
카르스텐 쉬메크
미하엘 투테볼
알렉산드로스 파칼로포울로스
올라프 베버
마르티나 부트케
Original Assignee
바이엘 헬스케어 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Application filed by 바이엘 헬스케어 아게 filed Critical 바이엘 헬스케어 아게
Publication of KR20070090248A publication Critical patent/KR20070090248A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077016219A 2004-12-18 2005-12-15 4-시클로알킬-치환된 테트라히드로퀴놀린 유도체 및 그의약제로서의 용도 Ceased KR20070090248A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000.2 2004-12-18
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004060997.7 2004-12-18

Publications (1)

Publication Number Publication Date
KR20070090248A true KR20070090248A (ko) 2007-09-05

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077016219A Ceased KR20070090248A (ko) 2004-12-18 2005-12-15 4-시클로알킬-치환된 테트라히드로퀴놀린 유도체 및 그의약제로서의 용도

Country Status (27)

Country Link
US (2) US8124775B2 (https=)
EP (1) EP1828137B1 (https=)
JP (1) JP5132317B2 (https=)
KR (1) KR20070090248A (https=)
AR (1) AR055011A1 (https=)
AT (1) ATE555097T1 (https=)
AU (1) AU2005315770B2 (https=)
BR (1) BRPI0519602A2 (https=)
CA (1) CA2591397A1 (https=)
CU (1) CU23452B7 (https=)
CY (1) CY1112887T1 (https=)
DK (1) DK1828137T3 (https=)
DO (1) DOP2005000259A (https=)
ES (1) ES2384980T3 (https=)
GT (1) GT200500377A (https=)
IL (1) IL184008A (https=)
MA (1) MA29100B1 (https=)
MX (1) MX2007007188A (https=)
NO (1) NO20073146L (https=)
PE (1) PE20060767A1 (https=)
PL (1) PL1828137T3 (https=)
PT (1) PT1828137E (https=)
RU (1) RU2393151C2 (https=)
SI (1) SI1828137T1 (https=)
TW (1) TW200635900A (https=)
UY (1) UY29276A1 (https=)
WO (1) WO2006063828A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519566A2 (pt) * 2004-12-18 2009-01-27 Bayer Healthcare Ag derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
BRPI0909105A2 (pt) * 2008-03-05 2015-08-25 Boehringer Ingelheim Int Derivados de piridina tricíclicos, composição farmacêutica e uso dos mesmos, bem como processos para preparar os ditos compostos e a dita composição farmacêutica
UY33229A (es) * 2010-02-19 2011-09-30 Boehringer Ingelheim Int Derivados de piridina tricíclicos, medicamentos que contienen tales compuestos, su uso y proceso pa ra su preparación
CA2804924C (en) * 2010-07-09 2016-06-28 Daiichi Sankyo Company, Limited Substituted pyridine compound
EP2675811A1 (en) 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
TWI570118B (zh) 2012-01-06 2017-02-11 第一三共股份有限公司 經取代之吡啶化合物的酸加成鹽
MX384679B (es) 2014-07-30 2025-03-14 Hoffmann La Roche Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
WO2025185022A1 (zh) * 2024-03-05 2025-09-12 维康平生(北京)生物科技有限公司 一种脂肪体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
BRPI0519566A2 (pt) * 2004-12-18 2009-01-27 Bayer Healthcare Ag derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp

Also Published As

Publication number Publication date
US20080255068A1 (en) 2008-10-16
US20120142728A1 (en) 2012-06-07
AU2005315770B2 (en) 2011-12-08
US8124775B2 (en) 2012-02-28
DOP2005000259A (es) 2006-11-15
IL184008A0 (en) 2007-10-31
PE20060767A1 (es) 2006-09-10
CA2591397A1 (en) 2006-06-22
RU2007127127A (ru) 2009-01-27
SI1828137T1 (sl) 2012-08-31
JP5132317B2 (ja) 2013-01-30
NO20073146L (no) 2007-09-18
AU2005315770A1 (en) 2006-06-22
IL184008A (en) 2012-03-29
ATE555097T1 (de) 2012-05-15
MA29100B1 (fr) 2007-12-03
EP1828137A1 (de) 2007-09-05
TW200635900A (en) 2006-10-16
UY29276A1 (es) 2006-07-31
PL1828137T3 (pl) 2012-09-28
DK1828137T3 (da) 2012-07-23
RU2393151C2 (ru) 2010-06-27
ES2384980T3 (es) 2012-07-16
GT200500377A (es) 2006-11-09
CY1112887T1 (el) 2016-04-13
MX2007007188A (es) 2007-08-14
EP1828137B1 (de) 2012-04-25
JP2008524145A (ja) 2008-07-10
BRPI0519602A2 (pt) 2009-02-25
CU23452B7 (es) 2009-12-01
PT1828137E (pt) 2012-07-04
WO2006063828A1 (de) 2006-06-22
AR055011A1 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
JP7532371B2 (ja) Ｔｈｒβ受容体アゴニスト化合物、およびその製造方法および使用
KR20070090192A (ko) (5ｓ)-3-[(ｓ)-플루오로(4-트리플루오로메틸페닐)메틸]-5,6,7,8-테트라히드로퀴놀린-5-올 유도체 및 이의 ｃｅｔｐ억제제로서의 용도
US20120142728A1 (en) Chemical compound and its use
US10000489B2 (en) Compounds αvβ6 integrin antagonists
KR101440633B1 (ko) 치환된 크로마놀 유도체 및 그의 용도
KR20070007112A (ko) 이상지혈증 치료를 위한 화합물 및 방법
EP3144303B1 (en) 6-substituted phenoxychroman carboxylic acid derivatives
WO2007032466A1 (ja) 複素環化合物、その製造方法並びに用途
KR20090106633A (ko) ＰＤＥ5 억제제로서 유용한 6-벤질-2,3,4,7-테트라히드로-인돌로[2,3-ｃ]퀴놀린 화합물
CN1147300C (zh) 玻连蛋白受体拮抗剂
US20050222418A1 (en) Novel tyloindicines and related processes, pharmaceutical compositions and methods
AU2011223895A1 (en) Fluorouracil derivatives
CN101124206B (zh) 4-环烷基取代的四氢喹啉衍生物及其作为药物的用途
JP2008024599A (ja) ピリダジノン誘導体、それらを有効成分とするｐｄｅ阻害剤及び医薬
US20110059019A1 (en) Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
HK1117832A (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
US5484924A (en) Imidazonaphthyridine derivatives
CN1938320A (zh) 用于治疗异常脂肪血症的化合物和方法
WO2017107877A1 (zh) 一种联苯衍生物及其制备方法和在医药上的用途
JPWO2000042025A1 (ja) ピリミジン誘導体からなるポリ（ａｄｐ−リボース）合成酵素阻害剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20090825

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120831

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130425

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130830

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130425

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20120831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I